We are live on
!
Find out more
CA
CHI Advisors Portfolio holdings
AUM
$252M
1-Year Est. Return
56.99%
This Fund
S&P 500
This Quarter
Est. Return
+14.4%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$330M
AUM Growth
-$47.1M
(-13%)
Cap. Flow
-$63.2M
Cap. Flow
% of AUM
-19.18%
Top 10 Holdings %
Top 10 Hldgs %
86.17%
Holding
32
New
8
Increased
6
Reduced
8
Closed
6
Avg Time Held Equity + Options
6.8
quarters
Top 10 Avg Time Held Equity + Options
5
quarters
Top 20 Avg Time Held Equity + Options
6.2
quarters
Avg Time Held Equity only
7.1
quarters
Top 10 Avg Time Held Equity only
5
quarters
Top 20 Avg Time Held Equity only
6.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACELYRIN
SLRN
|
+$54.5M |
| 2 |
Keros Therapeutics
KROS
|
+$6.18M |
| 3 |
Direxion Daily S&P Biotech Bear 3X ETF
LABD
|
+$4.85M |
| 4 |
Disc Medicine
IRON
|
+$4.44M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$3.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$100M |
| 2 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$32.5M |
| 3 |
Corvus Pharmaceuticals
CRVS
|
+$4.44M |
| 4 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$3.13M |
| 5 |
Kezar Life Sciences
KZR
|
+$2.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.53% |
| 2 | Miscellaneous | 1.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
FRLN
26
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
| $55.9K | 0.02% |
21,666
-293,629
| -93% | -$1.16M |
2020 Q3
11 quarters
|
|
|
27
DELISTED
Kezar Life Sciences
KZR
| – | – |
-68,945
| Closed | -$2.16M | – |
|
28
Entrada Therapeutics
TRDA
$189M
| – | – |
-56,374
| Closed | -$817K | – |
|
|
KDNY
29
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| – | – |
-135,000
| Closed | -$3.13M | – |
|
|
ONCR
30
DELISTED
Oncorus, Inc.
ONCR
| – | – |
-2,367,436
| Closed | -$815K | – |
|
|
RXDX
31
CALL
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| – | – |
-25,000
| Closed | -$108K | – |
|
|
RXDX
32
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| – | – |
-934,135
| Closed | -$100M | – |
|
Similar funds
SC
T
W
RBGI
TOGEPT
IAM
RCGI
AEPLI
CHI Advisors's Q2 2023 Portfolio in Review
As of Q2 2023, CHI Advisors held 32 positions worth $330M, down 13% from $377M the previous quarter. Its ten largest holdings account for 86% of the portfolio.
CHI Advisors withdrew a net $63.2M in Q2 2023, closing 6 positions and reducing 8 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $100M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, CHI Advisors opened a new position in ACELYRIN worth $55.7M.
- CHI Advisors's largest Q2 2023 buy was ACELYRIN: 2,663,806 shares worth $55.7M.
- CHI Advisors added most to Keros Therapeutics in Q2 2023, an estimated $6.18M increase.
- CHI Advisors's biggest Q2 2023 reduction was VectivBio Holding AG Ordinary Shares, cutting an estimated $32.5M.
- CHI Advisors fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $100M.
- CHI Advisors's ten largest holdings make up 86% of its $330M portfolio in Q2 2023.
- CHI Advisors opened 8 new positions and closed 6 in Q2 2023.
- CHI Advisors's portfolio value fell 13% quarter-over-quarter to $330M.
Based on CHI Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.